"Enrolment concludes in Belite Bio’s trial of Tinlarebant for geographic atrophy" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

The trial will evaluate the safety and tolerability of Tinlarebant and its potential to reduce atrophic lesion growth rate in ...

To schedule a one-on-one meeting with management, please reach out to your BTIG representative.

LBS-008 (aka Tinlarebant) is Belite Bio’s orally administered tablet for the treatment of Stargardt disease (STGD1) and Dry AMDA 2-year Phase 2 trial in adolescent STGD1 and a global Phase 3 ...

Belite Bio highlighted notable clinical progress in Q1 2025, with the PHOENIX trial nearing its 500-subject enrollment target and the DRAGON trial maintaining momentum following a positive DSMB ...

United States, the United Kingdom, France, Czech Republic, Switzerland, China, Taiwan, and Australia SAN DIEGO, July 02, 2025 ...

-LBS-008 (aka Tinlarebant) is Belite Bio’s orally administered tablet for the treatment of Stargardt disease (STGD1) and Dry AMD -A 2-year Phase 2 trial in adolescent STGD1 and a global Phase 3 ...

Maxim analyst Michael Okunewitch raised the firm’s price target on Belite Bio (BLTE) to $110 from $60 and keeps a Buy rating on the shares after its Q3 results. The company’s Phase 3 DRAGON ...

Belite Bio ended the third quarter with $109 million worth of cash and marketable securities on its balance sheet after posting a net loss of $8.7 million. The company had no long-term debt as of ...

Belite Bio Inc (NASDAQ: BLTE) stock falls after reporting Q3 net loss of $36.1M; analysts maintain Buy/Overweight rating, citing positive trial results.

Belite tracked a 70% reduction in RBP4 relative to baseline in Stargardt patients, offering encouragement that the drug hits its target, and saw no serious treatment-emergent adverse events or deaths.